At the ESMO 2026 Congress in Madrid, held from October 23 to 27, researchers presented findings suggesting the Decipher genomic test can help determine how aggressively to treat high-risk localized prostate cancer. The study aims to distinguish between patients who require intensive hormone therapy and those who can safely avoid it.
Balancing abiraterone's survival benefits against quality of life
The clinical utility of hormone therapy presents a difficult trade-off for oncology patients. As reported at the ESMO 2026 Congress, the therapy abiraterone has been shown in the STAMPEDE clinical trial to reduce the risk of death by half among men with high-risk, localized prostate cancer. However, the intensity of such treatment is not without cost.
Aggressive medical intervention can lead to increased side effects and a diminished quality of life for many patients. according to a UCL news release, not every cancer is identical, meaning that treating a patient more aggressively than their specific molecular profile requires could be counterproductive to their overall well-being.
Predicting cancer spread via 27,000 real-world patient profiles
The Decipher test provides a molecular roadmap that may allow for more personalized care . By analyzing data from more than 27,000 patients in real-world settings, alongside 401 men from a randomized clinical trial, researchers found that higher Decipher scores were a reliable predictor of worse outcomes. Specifically, higher scores indicated a greater likelihood that the cancer would spread.
Conversely, a low Decipher score suggests that intensive treatment might be unnecessary for certain individuals. Elai Davicioni, the medical director of urology for Veracyte—the manufacturer of the Decipher test—noted that this growing body of evidence gives physicians a stronger reason to utilize genomic testing before making decisions that impact both survival and patient lifestyle . The report notes that understanding who benefits most from additional treatment can make a meaningful difference in clinical outcomes.
How anti-androgens target localized mutations
Targeted therapies are increasingly being utilized to manage widespread prostate cancer, often employing powerful anti-androgens. As Dr. Marc Siegel, a senior medical analyst for Fox News,observed, these therapies work not only on the testes but also on the adrenals. He noted that localized prostate cancer may contain specific mutations that predict disease aggression and indicate potential responsiveness to these targeted treatments.
The scale of this issue is significant , as the American Cancer Society reports that approximately one in eight American men will face a prostate cancer diagnosis in their lifetime. Identifying the right patients for intensive therapy is therefore a major public health priority.
The necessity of validating Decipher scores in broader datasets
While the combination of randomized trial data and real-world datasets strengthens these findings, the medical community is not yet ready for universal implementation. Researcher Howlett noted that further validation across different, diverse datasets is required before the Decipher test can be used routinely to dictate treatment intensity. Until then, the test remains a powerful tool for research and guided decision-making rather than a standard-of-care requirement.
Comments 0